TABLE 2.
Laboratory and imaging features
| Number (%) | |
|---|---|
| Laboratory abnormalities | |
| Elevated inflammatory markers (see text) | 15 (40.5) |
| Lymphocytopenia | 12 (32.4) |
| Thrombocythemia | 2 (5.4) |
| Leukocytosis | 2 (5.4) |
| Hyponatremia | 1 (2.7) |
| MRI of the spine (n = 15) | |
| Normal | 9 (60.0) |
| Lumbosacral root enhancement | 2 (13.3) |
| Radiculitis and brachial/lumbosacral plexitis | 2 (13.3) |
| Leptomeningeal enhancement | 1 (6.7) |
| Myelopathy | 1 (6.7) |
| CT or MRI imaging of the brain (n = 14) | |
| Normal | 10 (71.4) |
| Facial nerve enhancement | 2 (14.3) |
| Cranial neuritis | 1 (7.1) |
| Enlargement, T2 hyperintensity, enhancement of CN III | 1 (7.1) |
| Cerebrospinal fluid (n = 33) | |
| Albuminocytologic dissociation | 25 (75.8) |
| Normal | 6 (18.2) |
| Pleocytosis | 2 (6.1) |
| SARS‐CoV‐2 PCR (n = 18) | 0 (0.0) |
Abbreviations: CN, cranial nerve; CT, computed tomography; MRI, magnetic resonance imaging; PCR, polymerase chain reaction; SARS‐CoV‐2, severe acute respiratory distress syndrome–coronavirus‐2.